QL0911

DRUG5 trials

Sponsors

Qilu Pharmaceutical Co., Ltd.

Conditions

Cancer Treatment-Induced ThrombocytopeniaChemotherapy-induced ThrombocytopeniaPrimary Immune ThrombocytopeniaThrombocytopenia, Immune

Phase 2

Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia

CompletedNCT05554913

Qilu Pharmaceutical Co., Ltd.Chemotherapy-induced Thrombocytopenia

Start: 2022-11-08End: 2024-02-20Updated: 2024-10-18

Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia

CompletedNCT05851027

Qilu Pharmaceutical Co., Ltd.Chemotherapy-induced Thrombocytopenia

Start: 2021-01-15End: 2021-09-10Updated: 2023-05-09

QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia

RecruitingNCT06456528

Qilu Pharmaceutical Co., Ltd.Cancer Treatment-Induced Thrombocytopenia

Start: 2024-10-22End: 2027-07-30Target: 235Updated: 2026-09-09

Phase 3

Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia

CompletedNCT05621330

Qilu Pharmaceutical Co., Ltd.Primary Immune Thrombocytopenia

Start: 2019-10-18End: 2021-12-16Updated: 2022-11-23

Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Not yet recruitingNCT07455006

Qilu Pharmaceutical Co., Ltd.Thrombocytopenia, Immune

Start: 2026-04-20End: 2028-03-10Target: 60Updated: 2026-03-06

Related Papers

A phase 2/3 study of romiplostim N01 in chemotherapy-induced thrombocytopenia (CIT).

JCO Oncology Practice2024-09-30

Efficacy and safety of QL0911 in adult patients with chronic primary immune thrombocytopenia: A multicenter, randomized, double-blind, placebo-controlled, phase III trial

Journal of Translational Internal Medicine2023-12-017 citations

P1596: EFFICACY AND SAFETY OF QL0911 IN ADULT PATIENTS WITH CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III TRIAL

HemaSphere2023-08-01